First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study GroupKenichi Kobayashi, T. Nukiwa, Satoshi Oizumi et al.|Journal of Clinical Oncology|2009Cited by 63
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.A. Inoue, Kenichi Kobayashi, Makoto Maemondo et al.|Journal of Clinical Oncology|2011Cited by 37
9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 studyA. Inoue, T. Nukiwa, Kenichi Kobayashi et al.|European Journal of Cancer Supplements|2009Cited by 15